Biohaven Ltd reports results for the quarter ended June 30 - Earnings Summary
Brief: Biohaven Reports Second Quarter 2025 Financial Results
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Brief: Biohaven Enrolls First Patient Into Phase 2/3 Trial In Early Parkinson's Disease
Brief: Biohaven Presents Oncology Program Updates And Preliminary Clinical Data
U.S. STOCKS ON THE MOVE-Plug Power, BGC Group, Paramount Group
U.S. STOCKS ON THE MOVE-Sable Offshore, Regeneron, Plug Power
U.S. STOCKS ON THE MOVE-Novavax, Reddit, BorgWarner
Biohaven falls after RBC downgrades on regulatory uncertainty
U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Boeing, Abbott
Biohaven drops after FDA extends review period for genetic disease drug
U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com
U.S. STOCKS ON THE MOVE-Walmart, Lockheed Martin, UnitedHealth Group
Biohaven drops after FDA extends review period for genetic disease drug
Brief: Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia
Biohaven Ltd reports results for the quarter ended March 31 - Earnings Summary
Brief: Biohaven Q1 Net Income USD -221.677 Million
U.S. STOCKS ON THE MOVE-Nvidia, Sabre, Biohaven